Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03TIS
|
|||
| Former ID |
DNAP001281
|
|||
| Drug Name |
Brentuximab vedotin
|
|||
| Synonyms |
Adcetris (TN)
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Hodgkin lymphoma [ICD-11: 2B30; ICD-10: C81, C81.9] | Approved | [1], [2], [3] | |
| Company |
Millennium Pharmaceuticals; Seattle Genetics
|
|||
| ADReCS Drug ID | BADD_D00291 | |||
| SuperDrug ATC ID |
L01XC12
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphocyte activation antigen CD30 (TNFRSF8) | Target Info | Modulator | [4] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TCR Signaling Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6772). | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 3 | ClinicalTrials.gov (NCT01990534) A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma. U.S. National Institutes of Health. | |||
| REF 4 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.